MASS 908 Devices Inc.

Medical Device Company
14.35
-0.96  -6%
Previous Close 15.31
Open 15.49
52 Week Low 12.6
52 Week High 45.09
Market Cap $450,696,161
Shares 31,407,398
Float 16,004,895
Enterprise Value $278,256,263
Volume 259,530
Av. Daily Volume 297,157
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Latest News

  1. Q1 2022 revenue increases 50% over prior year with Desktop revenue in BioPharma growing 68%

    908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended March 31, 2022.

    "We had a strong start to the year with revenue growing 50% over the prior year period. We made tangible progress against our goals as we continued to enable our customers with rapid chemical and biochemical analysis when and where they need it," said Kevin J. Knopp, CEO and Co-founder. "From global biopharma sites to prominent local events in our communities, like the Boston Marathon, our devices are being used to provide actionable insights…

    View Full Article
  2. Updates include new capabilities for iOS devices and expanded drug target list

    908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced updates to its MX908 handheld mass spec device, adding new capabilities to streamline workflows and improve field safety for first responders. The device will now include enhanced Bluetooth features with remote applications for iPhone mobile devices, as well as a broader range of drugs, including fentanyl analogs and synthetic opioids and cannabinoids.

    According to an issue brief from the American Medical Association, the opioid epidemic is now largely driven by fentanyl, methamphetamine and cocaine, often in…

    View Full Article
  3. Focus is on improving biotherapeutic process monitoring and control

    908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, is partnering with the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC), an academic-industry research consortium dedicated to implementing bioengineering innovations that enhance the development and manufacture of complex biotherapeutics. As part of this mission, researchers are now utilizing 908 Devices' REBEL™ analyzer to improve process monitoring and control methods in multiple AMBIC projects.

    AMBIC is developing enabling technologies, knowledge, design tools and methods that apply and integrate high-throughput and genome-based technologies…

    View Full Article
  4. 908 Devices Inc., (NASDAQ:MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the first quarter 2022 before market open on Tuesday, May 10, 2022. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

    Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event.

    About 908 Devices

    908 Devices is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications…

    View Full Article
View All 908 Devices Inc. News